<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095003</url>
  </required_header>
  <id_info>
    <org_study_id>L00070 IN 305 B0</org_study_id>
    <secondary_id>2008-004171-21</secondary_id>
    <nct_id>NCT01095003</nct_id>
  </id_info>
  <brief_title>Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer</brief_title>
  <official_title>A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line
      metastatic settings, led to a raise of patients presenting with metastatic breast cancer
      after treatment with these agents. Options for the treatment of patients who have progressed
      after an anthracycline and a taxane are limited. The high level of in-vitro synergy of
      vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the
      encouraging response rate observed while combining IV vinflunine to oral capecitabine make it
      a promising combination to investigate further in a phase III trial. This phase III trial
      will evaluate the effectiveness and the safety profile of such combination for the treatment
      of patient with advanced breast cancer previously treated with or resistant to anthracycline
      and taxane resistant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre, open-label, randomised, Phase III study will enrol 764 patients with
      advanced breast cancer who have previously been treated with or are resistant to an
      anthracycline and who are taxane resistant. Patients will be randomised in a 1:1 ratio to
      receive vinflunine plus capecitabine (Arm A) or capecitabine alone (Arm B).

      Randomisation will be stratified according to a minimization procedure:

        1. Resistance to anthracyclines (&quot;yes&quot; versus &quot;no&quot;), Relapse ≤ 12 months in the adjuvant or
           neoadjuvant setting or progression ≤ 4 months in the metastatic setting,

        2. Karnofsky performance status (&quot;90-100&quot; versus &quot;70-80&quot;),

        3. Measurable disease (&quot;yes&quot; versus &quot;no&quot;),

        4. The number of prior lines of chemotherapy in the metastatic setting (&quot;0&quot; versus &quot;1&quot;
           versus &quot;&gt; 1&quot;) and,

        5. Study site.

      Patients randomised in Arm A will receive:

        -  Vinflunine at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a
           20-minute i.v. infusion and,

        -  Capecitabine which will be self-administered by the patient in an outpatient setting.
           Patients will take 825 mg/m² twice daily per os for 14 consecutive days beginning on day
           1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.

      For patients randomised in Arm B, capecitabine will be self administered by the patient in an
      outpatient setting. Patients will take 1250 mg/m² twice daily per os for 14 consecutive days
      beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as
      3 weeks.

      The doses and timing of treatment will be modified based on toxicities experienced by the
      patient.

      Patients will be assessed for toxicity, tumour response and progression at regular intervals
      during treatment. Patients will be evaluated for safety if they received any study drug.
      Laboratory values, adverse events and other symptoms will be graded.

      Tumour response, progression-free survival and duration of response will be evaluated for all
      randomised patients. Tumour assessment is to be performed every 6 weeks (+/- 3 working days)
      from randomisation (regardless of the timing of treatment cycles) until disease progression
      is documented. Patients who discontinue protocol treatment for reasons other than disease
      progression will have tumour assessments every 6 weeks until documented disease progression.
      Patients may continue to receive additional cycles of therapy until progressive disease or
      intolerable toxicity.

      Quality of Life assessment, will be measured by EORTC QLQ-C30 and QLQ-BR23 questionnaires,
      which will be completed by patients.

      The primary endpoint for the trial is progression free survival calculated from the date of
      randomization until the date of progression or the date of death whatever the reason of
      death. The analysis of Progression-Free Survival is planned to take place when 615
      progressions or deaths have been observed. One interim safety analysis is planned and will
      take place when 50 patients of each arm have completed at least one cycle of study treatment.
      It is anticipated that up to 170 active study centres will participate, and that accrual will
      be completed in approximately 30 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline up to 2 years 7 months</time_frame>
    <description>PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.
The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline upto 3 years 10 months</time_frame>
    <description>The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline upto 2 years 7 months</time_frame>
    <description>ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Baseline up to 2 years 7 months</time_frame>
    <description>Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline up to 2 years 7 months</time_frame>
    <description>Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">770</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vinflunine plus Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received (in combination with capecitabine)
• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine single-agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine plus Capecitabine</intervention_name>
    <description>Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
    <arm_group_label>Vinflunine plus Capecitabine</arm_group_label>
    <other_name>JAVLOR</other_name>
    <other_name>L00070 IN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
    <arm_group_label>Capecitabine single-agent</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients

          -  21 years of age or older

          -  histologically/cytologically confirmed carcinoma of the breast

          -  documented locally recurrent or metastatic disease not amenable to curative surgery or
             radiotherapy

          -  either one, two or three prior chemotherapy regimens

          -  prior treatments including both an anthracycline and a taxane and patient no longer
             candidate for these drugs

          -  measurable or non-measurable disease according to RECIST 1.1

          -  Karnofsky performance score of at least 70 %

          -  adequate haematological, hepatic and renal functions

          -  ECG without clinically relevant abnormality

        Exclusion Criteria:

          -  known or clinical evidence of brain metastasis or leptomeningeal involvement

          -  pulmonary lymphangitis or symptomatic pleural effusion

          -  any serious, concurrent uncontrolled medical disorder

          -  history of second primary malignancy

          -  preexisting motor/sensory peripheral neuropathy

          -  known history of HIV infection

          -  prior therapy with capecitabine and/or vinca-alkaloids

          -  history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or
             contra indication to any of these drugs

          -  known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude VEDOVATO</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Medicament</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Martin</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calcutta</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patna</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fabriano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saltillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tambov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kimberley</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genolier</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khmelnytskyï</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keighley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southend-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <results_first_submitted>May 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2019</results_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vinflunine Plus Capecitabine</title>
          <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Capecitabine Single-agent</title>
          <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="386"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="386"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Capecitabine Single-agent</title>
          <description>Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Vinflunine Plus Capecitabine</title>
          <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="386"/>
            <count group_id="B2" value="384"/>
            <count group_id="B3" value="770"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="669"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="384"/>
                    <measurement group_id="B3" value="770"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.
The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.</description>
        <time_frame>Baseline up to 2 years 7 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Capecitabine</title>
            <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Single-agent</title>
            <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.
The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.3" upper_limit="6.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="4.1" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The final analysis of progression free survival was conducted once the required number of events(615 progressions or deaths) was reached.using the IRC assessment of date of progressions following the blinded radiological and clinical review of data. Kaplan-Meier curves and life tables by treatment arm were provided.A stratified Cox proportional model was used to compare the two treatment arms</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0426</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.</description>
        <time_frame>Baseline upto 3 years 10 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Capecitabine</title>
            <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Single-agent</title>
            <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="11.9" upper_limit="15"/>
                    <measurement group_id="O2" value="11.7" lower_limit="10.8" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7657</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.</description>
        <time_frame>Baseline upto 2 years 7 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Capecitabine</title>
            <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Single-agent</title>
            <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.</description>
          <population>ITT population</population>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="18.8" upper_limit="27.5"/>
                    <measurement group_id="O2" value="17.9" lower_limit="14.2" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate</title>
        <description>Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.</description>
        <time_frame>Baseline up to 2 years 7 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Capecitabine</title>
            <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Single-agent</title>
            <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate</title>
          <description>Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.</description>
          <population>ITT population</population>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="52.2" upper_limit="62.3"/>
                    <measurement group_id="O2" value="47.9" lower_limit="42.9" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0089</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.</description>
        <time_frame>Baseline up to 2 years 7 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Capecitabine</title>
            <description>Patients received (in combination with capecitabine)
• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.
Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Single-agent</title>
            <description>Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.</description>
          <population>ITT</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="52.2" upper_limit="62.3"/>
                    <measurement group_id="O2" value="47.9" lower_limit="42.9" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) are reported from time of first dose of study treatment up to the end of study period (treatment period + follow-up period) up to 5 years 9 months.</time_frame>
      <desc>AEs were collected from treated patients who received at least one dose of study treatment (383 patients in each arm). The same event may appear as both an AE and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as nonserious in another. Specific AE tables were generated separately as per European format.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vinflunine Plus Capecitabine</title>
          <description>Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Capecitabine Single-agent</title>
          <description>Capecitabine: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="384"/>
                <counts group_id="E2" subjects_affected="348" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Haemoytique anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Anginal pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Reflux gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Multi organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecytitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cholecystetis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemai</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lower respiaratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALAT increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>ASTT increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypokaelemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Malignant neoplasmprogression</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brachial plexopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>PPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anal fistula excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bile duct stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Central venous catherisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="383"/>
              </event>
              <event>
                <sub_title>PPES</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations and caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karim Keddad</name_or_title>
      <organization>Institut de Recherche Pierre Fabre</organization>
      <phone>+33.5.34.50.61.69</phone>
      <email>Karim.keddad@pierre-fabre.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

